[Immunosuppressive therapy in rheumatoid arthritis].
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000740:Anemia / Q000209:etiology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology*; D001772:Blood Cell Count; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007275:Injections, Intravenous; D007841:Latex Fixation Tests; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D013997:Time Factors; D014228:Triaziquone / Q000008:administration & dosage / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D014228:Triaziquone; D008727:Methotrexate
Immunsuppressive Therapie der rheumatoiden Arthritis.